Tag: PCSK9
-
In-vivo gene editing of the lipid axis — PCSK9, ANGPTL3 and Lp(a), and what a “one-shot, lifelong” lowering does and does not yet prove
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In-vivo gene editing is now reproducing, in a permanent, single-dose form, the “lipid biomarker lowering” that siRNA/ASO drugs already established. Two programs have reached peer review:…
Uthando Nethemba 